Literature DB >> 21908504

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

B Eichhorst1, M Dreyling, T Robak, E Montserrat, M Hallek.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21908504     DOI： 10.1093/annonc/mdr377

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  40 in total

1.  Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Authors:  Paula Cramer; Susanne Isfort; Jasmin Bahlo; Stephan Stilgenbauer; Hartmut Döhner; Manuela Bergmann; Martina Stauch; Michael Kneba; Elisabeth Lange; Petra Langerbeins; Natali Pflug; Gabor Kovacs; Valentin Goede; Anna-Maria Fink; Thomas Elter; Kirsten Fischer; Clemens-Martin Wendtner; Michael Hallek; Barbara Eichhorst
Journal:  Haematologica       Date:  2015-08-27       Impact factor: 9.941

2.  Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.

Authors:  Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

3.  High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia.

Authors:  Cheng Fang; Yun Zhuang; Li Wang; Lei Fan; Yu-Jie Wu; Run Zhang; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Wei Xu; Jian-Yong Li
Journal:  Cancer Sci       Date:  2013-06-07       Impact factor: 6.716

4.  Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.

Authors:  C Beauchemin; J B Johnston; M È Lapierre; F Aissa; J Lachaine
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

Review 5.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

6.  Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

Authors:  Christian Klein; Alfred Lammens; Wolfgang Schäfer; Guy Georges; Manfred Schwaiger; Ekkehard Mössner; Karl-Peter Hopfner; Pablo Umaña; Gerhard Niederfellner
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

Review 7.  Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 8.  The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.

Authors:  Jennifer R Brown; Florence Cymbalista; Jeff Sharman; Ira Jacobs; Pilar Nava-Parada; Anthony Mato
Journal:  Oncologist       Date:  2017-12-06

Review 9.  Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.

Authors:  Spencer H Bachow; Nicole Lamanna
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

10.  BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.

Authors:  Sara Samuel; Vladimir Beljanski; Julien Van Grevenynghe; Stephanie Richards; Fethia Ben Yebdri; Zhong He; Carmen Nichols; S Mehdi Belgnaoui; Courtney Steel; Marie-Line Goulet; April Shamy; Dawn Brown; Guillermo Abesada; Elias K Haddad; John Hiscott
Journal:  Mol Ther       Date:  2013-05-21       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.